Report Adverse Event or Product Quality Complaint   US Site   Global Site             

Header Logo
  • Prescribing Information
  • Therapy areas
    • All Therapeutic Areas
    • Cardiovascular, Renal and Metabolism
    • Immunology
    • Infection
    • Oncology
    • Rare Disease (Alexion)
    • Respiratory
  • Disease Education
  • Resources
    • Congress Library
    • Clinical Trials
    • Continuing Education
    • Patient Support
    • Pipeline
  • Connect
    • Connect with an MSL
    • Connect with an MSL
    • Submit an Medical Information Request
    • Give Feedback

Search Medical Information

Login

Request a field medical follow-up

  • Home
  • Congress Library
  • WCN 2026

World Congress of Nephrology (WCN) - 2026

March 28 - 31, 2026

  1. All
  2. Farxiga (dapagliflozin)
  3. Hypertension
  4. Chronic Kidney Disease

PDF

Defining the roles of SGLT2is and GLP-1 RAs in the management of chronic kidney disease with type 2 diabetes and overweight/obesity: A Delphi consensus

PDF

Evidence-based positioning of SGLT2is and GLP-1 RAs in the management of chronic kidney disease with type 2 diabetes and overweight/obesity: A systematic literature review

HTML

Evaluating the clinical, economic, and environmental impact of guideline-directed therapy in Japan: an IMPACT CKD analysis

HTML

Kidney hierarchical composite endpoint in Japanese participants: A post-hoc subgroup analysis from the DAPA-CKD trial

PDF

Efficacy and safety of the aldosterone synthase inhibitor baxdrostat in patients with uncontrolled or resistant hypertension

PDF

Baseline characteristics of participants in BaxAsia: phase 3 study of the aldosterone synthase inhibitor baxdrostat in adults with uncontrolled or resistant hypertension primarily from Asia

PDF

Effects on serum potassium and risk of hyperkalaemia with balcinrenone and dapagliflozin; a sub analysis of the Phase 2b MIRO-CKD trial in patients with CKD

HTML

Modelling the projected clinical and environmental burden of chronic kidney disease in Egypt and Morocco between 2025 and 2030

PDF

Defining the roles of SGLT2is and GLP-1 RAs in the management of chronic kidney disease with type 2 diabetes and overweight/obesity: A Delphi consensus

PDF

Evidence-based positioning of SGLT2is and GLP-1 RAs in the management of chronic kidney disease with type 2 diabetes and overweight/obesity: A systematic literature review

HTML

Evaluating the clinical, economic, and environmental impact of guideline-directed therapy in Japan: an IMPACT CKD analysis

HTML

Kidney hierarchical composite endpoint in Japanese participants: A post-hoc subgroup analysis from the DAPA-CKD trial

PDF

Efficacy and safety of the aldosterone synthase inhibitor baxdrostat in patients with uncontrolled or resistant hypertension

PDF

Baseline characteristics of participants in BaxAsia: phase 3 study of the aldosterone synthase inhibitor baxdrostat in adults with uncontrolled or resistant hypertension primarily from Asia

PDF

Effects on serum potassium and risk of hyperkalaemia with balcinrenone and dapagliflozin; a sub analysis of the Phase 2b MIRO-CKD trial in patients with CKD

HTML

Modelling the projected clinical and environmental burden of chronic kidney disease in Egypt and Morocco between 2025 and 2030

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Connessiallasalute.it

This site is intended for healthcare professionals practicing in the US.
©2026 AstraZeneca. All rights reserved.

US-107328
Last Updated 5/26

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities  

Survey Feedback

Your Privacy Choice

Consumer Health Data
Privacy Notice

Privacy Notice | Legal Notice | Cookie Preferences

Welcome to AstraZeneca Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

 

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

 

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?
This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am not a healthcare professional practicing in the United States